Michael C. Soulen, MD of the University of Pennsylvania discusses primary resection of tumor in the gut and how there…
Browsing: Acute Lymphoblastic Leukemia
Michael C. Soulen, MD of the University of Pennsylvania discusses that peptide receptor radionuclide therapy US approval expected early 2018…
Michael C. Soulen, MD of the University of Pennsylvania answers the question “Is PRRT Practice Changing?”. He summarizes that cost,…
Identifying the optimal means of introducing biosimilars is an issue facing all clinics. Biosimilar rituximab was introduced in Oxford, UK…
Biosimilar licensing represents a huge opportunity for the NHS to make vital cost savings. In this interview, recorded at the…
In this interview, Ms Man-Chie Chow from the Royal Surrey County Hospital, Guildford, UK gives a brief overview of the…
The method of how new medication is determined to be cost-effective serves a crucial role in drug access. Here, Ms…
Affordable treatment reduces the burden on the healthcare services and increases the chances of NICE approval. Speaking from the British…
Streamlining the administration process of drug price agreements can greatly reduce the labor of pharmacists. In this interview at the…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses Identifying Minimum Residual Disease using Flow Cytometry and Next Gen…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses the Role of Tandem Autologous Transplant and PFS and Overall…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses Radiolabeled CD45 in Stem Cell Transplant For High Risk Multiple…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses how Allogeneic Stem Cell Transplant with Busulfan may Possibly improve…
There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib…
With many promising novel therapeutic agents exiting pharmaceutical pipelines, a question that arises is whether standard chemotherapy regimens with long-term…
A novel BTK inhibitor, acalabrutinib, is showing promise in the early clinical trial stages for chronic lymphocytic leukemia (CLL). Speaking…
Antibody-chemotherapy combinations are a standard treatment for hematological malignancies, and with an increase in small molecules coming through the pharmaceutical…
Older patients with acute lymphoblastic leukemia (ALL) have significantly worse outcomes; thus, there is a great need for improved treatments…
In this interview, Susan OBrien, MD, of the University of California, Irvine, CA, talks to us about the next-generation PI3K?…
One of the controversies surrounding the use of minimal residual disease (MRD) is the optimal technique for its assessment. Speaking…
The use of minimal residual disease (MRD) status in the clinic and trials is a promising, yet controversial, area of…
The treatments available for smoldering multiple myeloma (MM) are limited, with typical recommendations of observation or enrollment in clinical trials.…
Next-generation sequencing (NGS) has been widely used in research for the past decade or more; however, its translation into the…
When FLT3 inhibitors were first on the horizon, expectations were high, with hopes that they would have a similar level…
The development of IDH inhibitors for acute myeloid leukemia (AML) has been a smoother journey than that for FLT3 inhibitors.…
Researchers and clinicians now recognize that AML comprises a multitude of subtypes. In this interview, Richard Stone, MD, of the…
In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, gives his forecast of the acute myeloid…
In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III…
Robert Z. Orlowski, MD, from MD Anderson Cancer Center discusses Phase III Trial for multiple myeloma and Busulfan + Melphalan…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses ZUMA-1 trial long term follow up and very few long…
Robert Z. Orlowski, MD, from MD Anderson Cancer Center discusses the phase II study in multiple myeloma and the combination…
Ruben Mesa, MD, from UT Health San Antonio Cancer Center discusses risks of toxicity with interferon and chronic low-grade toxicities…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses mechanics of CAR-T cell therapy and combining axi-cel with an…
Gareth Morgan, MD, from University of Arkansas for Medical Sciences discusses immunoactive treatments and bispecific antibodies, CAR-T cells, and monovalent…
Robert Z. Orlowski, MD, PhD, from MD Anderson Cancer Center discusses myeloma drugs for 2018 and anti-body drug conjugates, Bi-specific…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses the new chemotherapy combination works better than previous and information…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses FDA’s approval of Axi-Cel and 42% of patients have long-term…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses Pegylated Interferon Alfa-2a and the utilization of Interferon on…
Habte Yimer, MD from Texas Oncology discusses safety for the 1st cycle of CyBorD and how it decreases infusion time…
Aziz Nazha, MD from Cleveland Clinic discusses the importance of prognosis on oncology and the probability of outcome of disease…
Robert Z. Orlowski, MD from MD Anderson Cancer Center discusses Ixazomib for maintenance in multiple myeloma and Ixazomib maybe approved…
Gareth Morgan, MD from University of Arkansas for Medical Sciences discusses double-hit myeloma and bialellic activation of P-53, ISS stage…
Dr. Peter Lucas, Director of Laboratory Services & Principal Investigator at NSABP, discusses clinical trial testing.
Habte Yimer, MD from Texas Oncology discusses Phase 2 study of Daratumumab and assess good, partial, or better response after…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses developments with immunotherapy and lymphoid malignancies – Checkpoint inhibitors and…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Rituximab after Bendamustine – Rituximab maintenance improved PFS at the…
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses CAR-T cell therapy in large cell Lymphoma – 80 response…